Achieve Life Sciences (NASDAQ:QUIT) Stock Moved Up to Sell by Wall Street Zen

Wall Street Zen upgraded shares of Achieve Life Sciences (NASDAQ:QUIT) from a strong sell rating to a sell rating in a research report sent to investors on Saturday,Wall Street Zen reports.

QUIT has been the topic of several other research reports. Weiss Ratings started coverage on Achieve Life Sciences in a report on Wednesday. They issued a “sell (d-)” rating on the stock. Zacks Research initiated coverage on shares of Achieve Life Sciences in a report on Tuesday, November 10th. They issued a “hold” rating for the company. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Reduce”.

Achieve Life Sciences Stock Up 0.5%

Shares of NASDAQ QUIT traded up $0.03 during trading on Friday, hitting $6.32. The company had a trading volume of 775,892 shares, compared to its average volume of 1,263,103. Achieve Life Sciences has a fifty-two week low of $2.62 and a fifty-two week high of $8.64. The firm has a market cap of $695.39 million, a price-to-earnings ratio of -4.08 and a beta of 2.42. The company has a quick ratio of 0.95, a current ratio of 10.49 and a debt-to-equity ratio of 0.03.

Achieve Life Sciences Company Profile

Achieve Life Sciences is a clinical-stage biopharmaceutical company focused on developing treatments for nicotine dependence. Its lead product candidate, cytisinicline, is being studied as a potential aid for people seeking to stop smoking or using other nicotine products. Cytisinicline is a plant-derived compound that acts on nicotine receptors in the brain. The company is conducting clinical development with the goal of obtaining regulatory approval; the candidate is not an approved treatment.